Plasma phospholipid fatty acids and prostate cancer risk in the select trial

Journal of the National Cancer Institute

Volumn 105, Issue 15, 2013, Pages 1132-1141

  Brasky, Theodore M ^a,b   Darke, Amy K ^c   Song, Xiaoling ^b   Tangen, Catherine M ^c   Goodman, Phyllis J ^c   Thompson, Ian M ^d,e   Meyskens, Frank L ^f   Goodman, Gary E ^b,g   Minasian, Lori M ^h,i   Parnes, Howard L ^h,i   Klein, Eric A ^j   Kristal, Alan R ^b,g  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b Cancer Prevention Program   (United States)

^c SWOG STATISTICAL CENTER   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

^e UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g Department of Environmental Health ^*  (United States)

^h UNIVERSITY OF WASHINGTON   (United States)

ⁱ NATIONAL CANCER INSTITUTE   (United States)

^j LERNER RESEARCH INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; FATTY ACID; LINOLEIC ACID; OMEGA 3 FATTY ACID; PLACEBO; SELENIUM;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER PATIENT; CANCER PREVENTION; CANCER RISK; COHORT ANALYSIS; DISEASE ASSOCIATION; DOSE RESPONSE; FATTY ACID BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION;

AGED; CASE-CONTROL STUDIES; DIETARY SUPPLEMENTS; FATTY ACIDS, OMEGA-3; FATTY ACIDS, OMEGA-6; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEOPLASM GRADING; ODDS RATIO; PHOSPHOLIPIDS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; SELENIUM; TREATMENT FAILURE; UNITED STATES; VITAMIN E;

EID: 84881656596     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djt174     Document Type: Article

References (48)

1. Wang W, Bergh A, Damber JE. Morphological transition of proliferative inflammatory atrop y to high-grade intraepithelial neoplasia and cancer in human prostate. Prostate. 2009;69(13):1378-1386.
2. Sfanos KS, De Marzo AM. Prostate cancer and inflammation: the evidence. Histopathology. 2012;60(1):199-215.
3. Discacciati A, Orsini N, Wolk A. Body mass index and incidence of localized and advanced prostate cancer-a dose-response meta-analysis of prospective studies. Ann Oncol. 2012;23(7):1665-1671.
4. Gong Z, Neuhouser ML, Goodman PJ, et al. Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev. 2006;15(10):1977-1983.
5. Cao Y, Ma J. Body mass index, prostate cancer-specific mortality, and biochemical recurrence: a systematic review and meta-analysis. Cancer Prev Res (Phila). 2011;4(4):486-501.
6. Kristal AR, Gong Z. Obesity and prostate cancer mortality. Future Oncol. 2007;3(5):557-67.
7. Rothwell PM, Fowkes FG, Belch JF, et al. Effect of daily aspirin on longterm risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet. 2011;377(9759):31-41.
8. Mahmud SM, Franco EL, Aprikian AG. Use of nonsteroidal anti-inflammatory drugs and prostate cancer risk: a meta-analysis. Int J Cancer. 2010;127(7):1680-1691.
9. Bansal D, Undela K, D'Cruz S, et al. Statin use and risk of prostate cancer: a meta-analysis of observational studies. PLoS One. 2012;7(10):e46691.
10. MacLean CH, Newberry SJ, Mojica WA, et al. Effects of omega-3 fatty acids on cancer risk: a systematic review. JAMA. 2006;295(4):403-415.
11. Gerber M. Omega-3 fatty acids and cancers: a systematic update review of epidemiological studies. Br J Nutr. 2012;107(Suppl 2):S228-S239.
12. Brasky TM, Crowe FL, Kristal AR. n-3 Fatty acids and prostate cancer risk. Br J Nutr. 2012:108(9):1721.
13. Thiebaut AC, Rotival M, Gauthier E, et al. Correlation between serum phospholipid fatty acids and dietary intakes assessed a few years earlier. Nutr Cancer. 2009;61(4):500-509.
14. Brasky TM, Till C, White E, et al. Serum phospholipid fatty acids and prostate cancer risk: results from the prostate cancer prevention trial. Am J Epidemiol. 2011;173(12):1429-1439.
15. Remig V, Franklin B, Margolis S, et al. Trans fats in America: a review of their use, consumption, health implications, and regulation. J Am Diet Assoc. 2010;110(4):585-592.
16. Mozaffarian D, Katan MB, Ascherio A, et al. Trans fatty acids and cardiovascular disease. N Engl J Med. 2006;354(15):1601-1613.
17. Timbo BB, Ross MP, McCarthy PV, et al. Dietary supplements in a national survey: Prevalence of use and reports of adverse events. J Am Diet Assoc. 2006;106(12):1966-1974.
18. Qato DM, Alexander GC, Conti RM, et al. Use of prescription and overthe-counter medications and dietary supplements among older adults in the United States. JAMA. 2008;300(24):2867-2878.
19. Manson JE, Bassuk SS, Lee IM, et al. The VITamin D and OmegA-3 TriaL (VITAL): rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease. Contemp Clin Trials. 2012;33(1):159-171.
20. Moyad MA. An introduction to dietary/supplemental omega-3 fatty acids for general health and prevention: part II. Urol Oncol. 2005;23(1):36-48.
21. Moyad MA. An introduction to dietary/supplemental omega-3 fatty acids for general health and prevention: part I. Urol Oncol. 2005;23(1):28-35.
22. Lippman SM, Klein EA, Goodman PJ, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2009;301(1):39-51.
23. Lippman SM, Goodman PJ, Klein EA, et al. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). J Natl Cancer Inst. 2005;97(2):94-102.
24. Klein EA, Thompson IM Jr, Tangen CM, et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2011;306(14):1549-1556.
25. Gleason DF. Histologic grade, clinical stage, and patient age in prostate cancer. NCI Monogr. 1988;(7):15-8.
26. Kristal AR, King IB, Albanes D, et al. Centralized blood processing for the selenium and vitamin E cancer prevention trial: effects of delayed processing on carotenoids, tocopherols, insulin-like growth factor-I, insulin-like growth factor binding protein 3, steroid hormones, and lymphocyte viability. Cancer Epidemiol Biomarkers Prev. 2005;14(3):727-730.
27. Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem. 1957;226(1):497-509
28. Schlierf G, Wood P. Quantitative determination of plasma free fatty acids and trigylcerides by thin-layer chromatography. J Lipid Res. 1965;6(2):317-319.
29. Lepage G, Roy CC. Direct transesterification of all classes of lipids in a one-step reaction. J Lipid Res. 1986;27(1):114-120.
30. Breslow NE, Day NE. The analysis of case-control studies. In: Davis W, ed. Statistical Methods in Cancer Research. Lyon, France: International Agency for Research on Cancer; 1980.
31. Park SY, Wilkens LR, Henning SM, et al. Circulating fatty acids and prostate cancer risk in a nested case-control study: the Multiethnic Cohort. Cancer Causes Control. 2009;20(2):211-223.
32. Poole C, Greenland S. Random-effects meta-analyses are not always conservative. Am J Epidemiol. 1999;150(5):469-475.
33. Chow CK. Fatty acid composition of plasma phospholipids and risk of prostate cancer. Am J Clin Nutr. 2009;89(6):1946; author reply 1946-1947.
34. Patterson E, Wall R, Fitzgerald GF, et al. Health implications of high dietary omega-6 polyunsaturated fatty acids. J Nutr Metab. 2012; Epub April 5, 2012.
35. Chavarro JE, Stampfer MJ, Li H, et al. A prospective study of polyunsaturated fatty acid levels in blood and prostate cancer risk. Cancer Epidemiol Biomarkers Prev. 2007;16(7):1364-1370.
36. Crowe FL, Allen NE, Appleby PN, et al. Fatty acid composition of plasma phospholipids and risk of prostate cancer in a case-control analysis nested within the European Prospective Investigation into Cancer and Nutrition. Am J Clin Nutr. 2008;88(5):1353-1363.
37. Harvei S, Bjerve KS, Tretli S, et al. Prediagnostic level of fatty acids in serum phospholipids: omega-3 and omega-6 fatty acids and the risk of prostate cancer. Int J Cancer. 1997;71(4):545-551.
38. Laaksonen DE, Laukkanen JA, Niskanen L, et al. Serum linoleic and total polyunsaturated fatty acids in relation to prostate and other cancers: a population-based cohort study. Int J Cancer. 2004;111(3):444-450.
39. Mannisto S, Pietinen P, Virtanen MJ, et al. Fatty acids and risk of prostate cancer in a nested case-control study in male smokers. Cancer Epidemiol Biomarkers Prev. 2003;12(12):1422-1428.
40. Crowe FL. Reply to CK Chow. Am J Clin Nutr. 2009;89(6):1946-1947.
41. Gann PH, Hennekens CH, Sacks FM, et al. Prospective study of plasma fatty acids and risk of prostate cancer. J Natl Cancer Inst. 1994;86(4): 281-286.
42. Chavarro JE, Stampfer MJ, Campos H, et al. A prospective study of transfatty acid levels in blood and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2008;17(1):95-101.
43. King IB, Kristal AR, Schaffer S, et al. Serum trans-fatty acids are associated with risk of prostate cancer in beta-Carotene and Retinol Efficacy Trial. Cancer Epidemiol Biomarkers Prev. 2005;14(4):988-992.
44. Calder PC, Yaqoob P. Omega-3 polyunsaturated fatty acids and human health outcomes. Biofactors. 2009;35(3):266-272.
45. Schwertner HA, Mosser EL. Comparison of lipid fatty acids on a concentration basis vs weight percentage basis in patients with and without coronary artery disease or diabetes. Clin Chem. 1993;39(4):659-663.
46. Raatz SK, Bibus D, Thomas W, et al. Total fat intake modifies plasma fatty acid composition in humans. J Nutr. 2001;131(2):231-234.
47. Hodson L, Skeaff CM, Fielding BA. Fatty acid composition of adipose tissue and blood in humans and its use as a biomarker of dietary intake. Prog Lipid Res. 2008;47(5):348-380.
48. Rizos EC, Ntzani EE, Bika E, et al. Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. JAMA. 2012;308(10):1024-1033.